1 Original article

2 Pharmacokinetics-based identification of antiviral

3 compounds of *Rheum palmatum* rhizomes and roots

4 (Dahuang)

- 5 Nan-Nan Tian^{a,b,1}, Ling-Ling Ren^{b,c,1}, Ya-Xuan Zhu^{a,b,1}, Jing-Ya Sun^{d,1},
- 6 Jun-Lan Lu^{a,b}, Jia-Kai Zeng^b, Feng-Qing Wang^b, Fei-Fei Du^b, Xi-He
- 7 Yang^{b,c}, Shu-Ning Ge^d, Rui-Min Huang^{d,***}, Wei-Wei Jia^{b,**}, Chuan
- 8 Li^{a,b,c,e,*}
- 9 ^aGraduate School, Tianjin University of Traditional Chinese Medicine, Tianjin,
- 10 300193, China
- ¹¹ ^bState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica,
- 12 Chinese Academy of Sciences, Shanghai, 201203, China
- 13 ^cSchool of Pharmacy, University of Chinese Academy of Sciences, Beijing, 100049,
- 14 China
- 15 ^dCenter for Drug Safety Evaluation and Research, Shanghai Institute of Materia
- 16 Medica, Chinese Academy of Sciences, Shanghai, 201203, China
- 17 °Haihe Laboratory of Modern Chinese Medicine, Tianjin 301617, China
- 18
- 19
- 20
- 21
- 22 * Corresponding author.
- 23 State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica,
- 24 Chinese Academy of Sciences, Shanghai, 201203, China.
- 25 ****** Corresponding author.
- 26 ******* Corresponding author.
- 27 E-mail addresses: rmhuang@simm.ac.cn (R-M. Huang), weiweijia@simm.ac.cn
- 28 (W-W. Jia), chli@simm.ac.cn (C. Li).
- 29 ¹ These authors contributed equally to this work. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

30 Abstract

31 The potential of Dahuang to eliminate lung pathogens was often highlighted in Wenyi Lun. This investigation aimed to identify potential antiviral compounds of 32 herbal component Dahuang (Rheum palmatum rhizomes and roots) 33 of 34 LianhuaQingwen capsule, with respect to their systemic exposure and lung 35 reachability. Circulating Dahuang compounds were identified in human volunteers 36 receiving LianhuaQingwen. The reachability of these compounds to SARS-CoV-2 37 3CL^{pro} was assessed by *in vitro* transport, metabolism, immunohistochemistry, and 3CL^{pro}-biochemical studies. LianhuaQingwen contained 55 Dahuang constituents 38 39 $(0.01-2.08 \mu mol/day)$, categorized into eight classes. Only three compounds rhein (3), 40 methylisorhein (10; a new Dahuang anthraquinone), and 4-O-methylgallic acid (M42_{M2}) exhibited significant systemic exposure in humans. Two intestinal 41 42 absorption mechanisms for 3 and 10 were proposed: active intestinal uptake of 3/10 by human TAUT/ASBT and human MRP1/3/4, and intestinal lacate-phlorizin 43 hrdrolyase-mediated hydrolysis of rhein-8-O-β-D-glucoside (9), followed by the 44 transporter-mediated absorption of released 3. Targeted reachability of circulating 45 46 3/10 could be achieved as rat orthologues of human ASBT/TAUT was observed in 47 alveolar and bronchial epithelia. These compounds exhibited potential ability to inhibit the 3CL^{pro} enzyme responsible for coronaviral replication. Notably, Dahuang 48 49 anthraquinones and tannins varied greatly in pharmacokinetics between humans and rats after dosing LianhuaQingwen. This investigation, along with such investigations 50 of other components, has implications for precisely defining the therapeutic benefits 51 52 of Dahuang-containing medicines.

- 53
- 54

Abbreviations: 3CL^{pro}, 3-chymotrypsin-like protease; ASBT/Asbt, apical
 sodium-dependent bile acid transporter; TAUT/Taut, taurine transporter.

- 57
- 58
- 59

Keywords: Rhein; methylisorhein; *Rheum palmatum*; Dahuang; Rhubarb;
LianhuaQingwen; 3CL^{pro}; COVID-19

- 1 -

62 **1. Introduction**

63 Dahuang (Rhubarb) has been used in traditional Chinese medicine for over 2000 64 years. Its medicinal properties and various applications were first recorded in the Divine Husbandman's Classic of Materia Medica (Shen Nong Ben Cao Jing) during 65 66 the Han Dynasty. The medicinal herb is obtained from the dried roots and rhizomes of 67 three species: Rheum palmatum L., Rheum tanguticum Maxim. ex Balf., and Rheum officinale Baill, which are included in the 2020 Chinese Pharmacopeia [1, 2]. 68 69 According to the Epidemic Febrile Disease (Wenyi Lun) in the Ming Dynasty, 70 Dahuang was used to eliminate pestilential qi due to its penetrating properties without 71 detainment [3]. This theory proposed that "epidemic disease" was caused by the 72 infection of pestilential qi, which referred to an exogenous disease pathogen that was 73 highly contagious and had an unpredictable epidemic pattern. Modern research 74 provided evidence suggesting that Dahuang extracts possessed inhibitory activity 75 against the 3-chymotrypsin-like protease (3CL^{pro}) of severe acute respiratory syndrome coronavirus (SARS-CoV) [4]. Furthermore, an integrated computational 76 77 study revealed that 13 natural anthraquinones, including chrysophanol, emodin, 78 aloe-emodin, rhein, and alterporriol Q, exhibited promising potential as inhibitors of 3CL^{pro} of SARS-CoV-2 [5]. The application and findings indicated that Dahuang 79 compounds might possess promising antiviral properties in humans. Additionally, the 80 81 rapid development of modern science unraveled numerous pharmacological activities 82 associated with Dahuang, including its purgative effects, anti-inflammatory properties, 83 hepatoprotective benefits, and positive impacts on the gallbladder. Dahuang was used 84 in clinical settings to treat constipation, severe acute pancreatitis, sepsis, and chronic liver and kidney diseases due to its extensive pharmacological effects [1, 6-8]. 85

Dahuang has mainly been used for medicinal purposes in Asia, but it often refers to a few edible Dahuang in Europe and the Middle East [6, 7]. Concerns regarding the safety of Dahuang have arisen due to reports suggesting potential liver and kidney toxicity associated with long-term high-dose administration of Dahuang in rats, prompting global scrutiny on its safety profile [1, 6, 9].

91 LianhuaQingwen capsule, a traditional Chinese medicine that contains Dahuang, 92 has been widely used in China for the treatment of acute respiratory viral infections caused by various viruses, including SARS-CoV, MERS-CoV, influenza A virus 93 94 (including H1N1 and H7N9), and more recently, SARS-CoV-2 [10, 11]. Several 95 clinical investigations reported the potential of the capsule as a valuable treatment 96 option for both COVID-19 and influenza patients. Its ability to improve viral clearance, alleviate symptoms, and reduce inflammatory markers makes it a 97 98 promising addition to conventional care [12-16]. In a recent prospective, multicenter, 99 randomized controlled trial of 284 patients with COVID-19, adding LianhuaQingwen 100 to conventional care further improved the recovery rate of symptoms, shortened the time to symptom recovery, and improved the recovery of chest radiologic 101 102 abnormalities (P < 0.05 for all) [12]. Treatment of the capsule in influenza patients was found to reduce the levels of serum inflammatory factors C-reactive protein, IL-6, 103 104 and procalcitonin [16]. In a cell-based study, LianhuaQingwen demonstrated 105 inhibition of SARS-CoV-2 replication and induced abnormal particle morphology of the virion [17]. Additionally, several circulating constituents of LianhuaQingwen, 106 including rhein, forsythoside A, forsythoside I, and neochlorogenic acid, were 107 108 identified as inhibitors of the host target cell-surface protein known as angiotensin 109 converting enzyme 2 receptor [18], to which the SARS-CoV-2 spike protein binds.

110 LianhuaQingwen capsule is derived from 13 herbal components and possesses

- 2 -

111 complex chemical composition. For systemic treatment of acute respiratory viral 112 infection with LianhuaQingwen, identification of circulating compounds in unchanged and/or metabolized forms is vital for facilitating their access to the loci 113 114 responsible for therapeutic effects. To this end, comprehensive understanding of chemical composition of LianhuaQingwen and better evaluation of pharmacokinetics, 115 disposition, and targeted reachability of its bioavailable compounds are vital for 116 117 translating the potential benefits of the capsule into therapeutic application. Successful identification of such constituents necessitates a comprehensive approach 118 119 to the multi-compound pharmacokinetic investigation of herbal medicine such that the 120 potentially important herbal compounds are singled out with their accurate 121 pharmacokinetic and disposition data and that no such compound is missed (in a few 122 words. 'precision without omission') [19-30]. In our ongoing series of 123 multi-compound pharmacokinetic inveatigations on LianhuaQingwen, we have 124 previously conducted research on the constituents originating from the herbal 125 component Gancao in humans after dosing the capsule [20]. In this current 126 investigation, our focus is on the component Dahuang, with the aim of identifying the 127 compounds that are likely to have therapeutic significance. Dahuang is extensively used as an herb in Chinese herbal medicines as well as dietary products. Therefore, 128 129 further research is necessary to elucidate the specific compounds responsible for its 130 pharmacological effects. This research has important implications for the safe 131 utilization of Dahuang-containing herbal medicines. Specifically, this pharmacokinetic investigation aimed to identify bioavailable Dahuang compounds 132 133 that have systemic exposure and targeted reachability, and are likely to influence the 134 therapeutic outcomes of Dahuang-containing herbal medicines, such as 135 LianhuaQingwen.

136 **2. Materials and methods**

137 A detailed description of materials and experimental procedures is provided in the

- 138 Supplementary Materials and methods.
- 139 2.1. Study materials

140 LianhuaQingwen capsules are produced by Shijiazhuang Yiling Pharmaceutical 141 Chinese NMPA drug ratification Co., Ltd and have а number of 142 GuoYaoZhunZi-Z20040063. Samples of LianhuaQingwen capsules were obtained 143 from the manufacturer, along with individual samples of the herbal components, and 144 stored at -20°C until analysis to assess their chemical composition and lot-to-lot 145 variability. Purified compounds found in *Rheum* species were obtained commercially (Table S1). One such compound, 3,8-dihydroxy-1-methylanthraquinone-2-carboxylic 146 147 acid (methylisorhein), was extracted and isolated from Dahuang (R. palmatum 148 rhizomes and roots) (Table S2).

Caco-2 cells and HEK-293 cells were obtained from American Type Culture 149 150 Collection (Manassas, VA, USA). Various human transporter cDNAs and human 151 enzyme cDNA lactase-phlorizin hydrolase (LPH) were constructed commercially. Inside-out membrane vesicles expressing human ATP-binding cassette transporter 152 were purchased from GenoMembrane (Kanazawa, Japan). Pooled human liver 153 microsomes (HLM) and pooled human liver cytosol (HLC) were obtained from 154 155 Corning Gentest (Woburn, MA, USA). Commercially available positive substrates for 156 these transporters and enzymes were also obtained.

157 2.2. Human pharmacokinetic study

158 A pharmacokinetic study on LianhuaQingwen capsule was conducted at Hebei 159 Yiling Hospital (Shijiazhuang, Hebei Province, China). The study was approved by the hospital's ethics committee and registered with the Chinese Clinical Trials 160 161 Registry (ChiCTR1900021460), following the Declaration of Helsinki. Fourteen healthy volunteers participated in the study after providing written informed consent. 162 The study details have been previously described [20]. Briefly, the participants 163 164 received a single dose of 12 capsules of LianhuaQingwen on day 1 and days 3-8. 165 Blood samples were collected before and at various time points after dosing on day 1, 166 and urine samples were collected within specific time periods. On days 3-7, blood 167 samples were collected before and 12 hours after dosing. On day 8, both blood and 168 urine samples were collected according to the respective time schedules on day 1. The 169 samples were treated and stored for analysis by liquid chromatography/mass 170 spectrometry at -70° C.

171 *2.3.* Supportive in vitro transport and metabolism studies

172 2.3.1. Transport study using Caco-2 cell monolayers

173 The membrane permeability of Dahuang compounds, including chrysophanol (1; 5 μ mol/L), emodin-8-O- β -D-glucoside (2; 50 μ mol/L), rhein (3; 5 μ mol/L), 174 175 chrysophanol-8-O-β-D-glucoside (4; 50 μmol/L), emodin (5; 5 μmol/L), 176 physcion-8-O-β-D-glucoside (6; 50 μmol/L), chrysophanol-1-O-β-D-glucoside (7; 50 μmol/L), physcion (8; 5 μmol/L), rhein-8-O-β-D-glucoside (9; 50 μmol/L), 177 178 methylisorhein (10; 5 µmol/L), and aloe-emodin (11; 5 µmol/L), was assessed using Caco-2 cell monolayers. The cells were cultured and the integrity of the cell 179 monolayers was measured. The apparent permeability coefficient (P_{app}) of each test 180 - 2 -

181 compound was calculated (Supplementary Materials and methods). The test compounds were classified into three categories based on their P_{app} values: low, 182 183 intermediate, or high membrane permeability [21]. The efflux ratio (EfR) was calculated and used to determine the possible involvement of a transporter-mediated 184 efflux mechanism. Verapamil, MK571, and novobiocin were added to inhibit ABC 185 186 transporters multidrug resistance protein 1 (MDR1), multidrug resistance-associated protein 2 (MRP2), and breast cancer resistance protein (BCRP). Atenolol and 187 antipyrine were used as low and high permeability reference compounds, respectively, 188 189 while rhodamine 123, sulfasalazine, and estrone-3-sulfate were used as probe 190 substrates of MDR1, MRP2, and BCRP, respectively. The experimental details have 191 been previously described [31].

192 2.3.2. Transport studies using cells transfected with SLC transporters or membrane
193 vesicles expressing ABC transporters

Cellular uptake of chrysophanol (1; $5 \mu mol/L$), emodin-8-*O*- β -D-glucoside (2; 50) 194 195 μ mol/L), rhein (3; 5 μ mol/L), chrysophanol-8-O- β -D-glucoside (4; 50 μ mol/L), 196 physcion-8-*O*-β-D-glucoside emodin (5; 5 μmol/L), (6; 50 μ mol/L), 197 chrysophanol-1-O- β -D-glucoside (7; 50 μ mol/L), physcion (8; 5 μ mol/L), 198 rhein-8-O-β-D-glucoside (9; 50 μmol/L), methylisorhein (10; 5 μmol/L), aloe-emodin 199 (11; 5 μ mol/L), gallic acid (42; 5 μ mol/L), and 4-O-methylgallic acid (M42_{M2}; 5 µmol/L) was assessed using human apical sodium-dependent bile acid transporter 200 (ASBT)-, taurine transporter (TAUT)-, organic anion-transporting polypeptide 2B1 201 (OATP2B1)-, organic anion transporter 1 (OAT1)-, OAT2-, OAT3-, OAT4-, organic 202 - 3 -

203	cation transporter 2 (OCT2)-, peptide transporter 1 (PEPT1)-, and PEPT2-transfected
204	HEK-293 cells. In addition, vesicular transport of 3 (5 $\mu mol/L)$ and 10 (5 $\mu mol/L)$
205	was assessed using vesicles expressing human MDR1, BCRP, MRP1, MRP2, MRP3,
206	or MRP4. All the incubation samples were analyzed by liquid chromatography/mass
207	spectrometry. The experimental details have been previously described [32, 33].

208 2.3.3. Metabolism studies

209	The	deglycosylation	of	emodin-8- <i>O</i> -β-D-glucoside	(2),
210	chrysophano	l-8-0-β-D-glucoside	(4),	physcion-8- <i>O</i> -β-D-glucoside	(6),
211	chrysophano	l-1- <i>O</i> -β-D-glucoside ('	7), or rhe	in-8- O - β -D-glucoside (9), each	at 1
212	µmol/L, was	assessed using recomb	inant huma	n LPH. Glucuronidation, sulfatio	n, and
213	oxidation of	rhein (3) or methylison	rhein (10),	each at 1 µmol/L, were assessed	using
214	UDPGA-for	tified HLM, PAPS-for	rtified HL	C, and NADPH-fortified HLM	. The
215	detailed incu	bation conditions were	described p	previously [30].	

216 2.4. Supportive rat pharmacokinetic studies

Rat pharmacokinetic study on LianhuaQingwen capsule was conducted at
Laboratory Animal Center of Shanghai Institute of Materia Medica (Shanghai, China).
Three studies were approved by the Institutional Animal Care and Use Committee,
following the Guidelines for Ethical Treatment of Laboratory Animals by the Ministry
of Science and Technology of China. Femoral artery cannulation or bile duct
cannulation was performed to collect rat blood or bile, respectively [23]. In these
three rat studies, all the rats were given an oral dose of LianhuaQingwen at 3.78 g/kg.

The first study involved the collection of serial blood samples before and at various time points after dosing. The blood samples were treated and centrifuged to produce plasma samples. The second study involved the collection of serial urine samples within specific time periods after dosing. The third study involved the collection of serial bile samples within specific time periods after dosing. The samples were stored for analysis by liquid chromatography/mass spectrometry at -70° C.

230 2.5. Assay for composition analysis of Dahuang constituents in LianhuaQingwen

The composition analysis of LianhuaQingwen for constituents originating from the component Dahuang was conducted using liquid chromatography/mass spectrometry. A literature-derived list of candidate compounds was used to guide the analysis, and a comprehensive detection approach was employed to identify all constituents present in the sample. The detected constituents underwent characterization and quantification for ranking and grading. Fourteen capsule lots were analyzed to assess inter-lot variability.

238 *2.6. Bioanalytical assays for analyses of Dahuang compounds and other study*

239 *compounds*

240 pharmacokinetics The of Dahuang compounds in LianhuaQingwen 241 administration was investigated through two types of bioanalyses. The first type involved profiling unchanged and metabolized Dahuang compounds in human/rat 242 243 samples. This was accomplished utilizing the Acquity ultra performance liquid 244 chromatographic separation module/Waters Synapt G2 mass spectrometer to detect,

- 5 -

245 characterize, and quantify the compounds. The second type involved quantifying 246 specific Dahuang compounds in human/rat samples and in vitro samples using an 247 Applied Biosystems Sciex Triple Quad 5500 mass spectrometer interfaced with an Agilent 1290 Infinity II LC system. The concentrations of various reference 248 249 compounds in study samples analyzed using liquid in vitro were 250 chromatography/mass spectrometry. Assay validation, implemented according to the 251 European Medicines Agency Guideline on bioanalytical method validation (2012), 252 demonstrated that the quantification assays developed were reliable and reproducible for the intended use, despite no internal standard being used. 253

254 2.7. In vitro assessment of SARS-CoV-2 3CL^{pro} protease inhibition

255 The proteolytic activity of the 3-chymotrypsin-like protease (3CL^{pro}) of 256 SARS-CoV-2 was assessed with a fluorescence resonance energy transfer (FRET) 257 assay. The activity of recombinant SARS-CoV-2 3CL^{pro} was evaluated in cleaving a synthetic fluorogenic peptide substrate MCA-AVLOSGFR-Lys(Dnp)-Lys-NH₂, which 258 was derived from the N-terminal auto-cleavage sequence from the viral protease. The 259 260 cleaved MCA peptide fluorescence was measured by a SpectraMax M2 microplate 261 reader (Molecular Devices; CA, USA) at an excitation wavelength of 325 nm and an emission wavelength of 393 nm. The assay reaction buffer contained 50 mM Tris-HCl 262 263 (pH 7.3), 1 mM EDTA, and 20 µM peptide substrate. Enzymatic reactions were initiated with the addition of 100 nM SARS-CoV-2 3CL^{pro} and allowed to proceed at 264 265 37 °C for 10 min (under linear cleavage condition). The Michaelis-Menten constant of the peptide substrate for SARS-CoV-2 3CL^{pro} was measured to determine the 266 267 substrate concentration used in the following inhibition assessment. Ebselen, a

268 positive inhibitor of SARS-CoV-2 3CL^{pro}, decreased the fluorescence. The inhibition potencies of the test Dahuang compounds, such as rhein (3), methylisorhein (10), 269 aloe-emodin (11), 4-O-methylgallic acid ($M42_{M2}$), and gallic acid (42), were initially 270 screened at a concentration of 100 μ mol/L. The Dahuang compounds that showed \geq 271 50% inhibition in the initial screening were further evaluated at multiple 272 273 concentrations for their half-maximal inhibitory concentrations (IC₅₀) for 274 SARS-CoV-2 3CL^{pro}. For the IC₅₀ assessment, the recombinant protease was 275 incubated with the peptide substrate at 1.4 μ mol/L (the K_m for SARS-CoV-2 3CL^{pro}) 276 in the presence or absence of the test Dahuang compound.

277 2.8. Western blot

278 HEK-293 cells were transfected with empty vector, human Flag-ASTB, human 279 Flag-TAUT, rat Flag-ASBT, or rat Flag-TAUT plasmids for 48 hours. After that, the 280 cells were harvested and lysed with RIPA lysis buffer (pH 7.5) containing 150 mM NaCl, 1 mM Na₃VO₄, 50 mM Tris-HCl, 25 mM NaF, 1% NP-40, 0.5% sodium 281 282 deoxycholate, 0.1% SDS, and 1% phosphatase inhibitor cocktails. Rat lung, bronchus, liver, and intestine were collected and lysed in the same RIPA lysis buffer using a 283 284 grinder. Subsequently, 20 µg of the aforementioned proteins were loaded onto 285 SDS-PAGE and transferred to nitrocellulose membranes (Millipore, Billerica, MA, 286 USA). The membranes were then incubated overnight at 4°C with primary antibodies against ASBT (1:1000, 25245-1-AP; Proteintech, Wuhan, Hubei Province, China) or 287 288 TAUT (1:1000, PA5-98161; Invitrogen, Waltham, MA, USA). For detection, the membranes were treated with secondary antibodies conjugated to horseradish 289

290	peroxidase (Jackson, West Grove, PA, USA) and the immunoreactive proteins were
291	visualized using the West Pico PLUS Chemiluminescent Substrate (Thermo, Waltham,
292	MA, USA) and imaged using chemiluminescent imaging.

293 *2.9. Immunohistochemistry*

294 Rat lung and intestine tissues were fixed in 4% paraformaldehyde and embedded 295 in paraffin. The tissues were then sectioned into 5 µm thick paraffin sections and deparaffinized. Antigen retrieval was performed using Tris-EDTA (pH 9.0). For 296 297 immunohistochemistry staining, the sections were incubated with primary antibodies 298 against ASBT (1:100, AB203205; Abcam, Cambridge, UK) or TAUT (1:500, 299 PA5-98161; Invitrogen, Waltham, MA, USA), followed by incubation with 300 biotinylated goat anti-rabbit IgG as secondary antibodies. Signals were amplified using a DAB kit (Maixin Bio, Fuzhou, Fujian Province, China) and counterstained 301 302 with hematoxylin.

303 2.10. Data Processing

304 After conducting the composition analysis, the detected and characterized 305 Dahuang constituents were ranked and graded into different levels based on their 306 daily doses. The daily compound dose was calculated by multiplying the compound level in LianhuaQingwen and the capsule's label daily dose of 4.2 g/day. 307 308 Noncompartmental analysis was used to estimate pharmacokinetic parameters of 309 Dahuang compounds. Renal clearance ratio (R_{rc}) was calculated using renal clearance, 310 glomerular filtration rate [34], and unbound fraction in human plasma. Data are 311 expressed as mean \pm standard deviation, and statistical analysis was performed using

- 312 a two-tailed unpaired Student t-test. A value of P < 0.05 was considered statistically
- 313 significant.

314 **3. Results**

315 *3.1.* Constituents originating from Dahuang and their abundance in LianhuaQingwen

316	Based on the composition analysis conducted, a total of 55 constituents that
317	originated from the Dahuang component were detected and characterized in samples
318	of LianhuaQingwen (Fig. 1 and Table S3). These constituents were divided into eight
319	classes, including anthraquinones (1-22), anthrones (31-34), tannins (41-52),
320	flavonoids (61-64), naphthalenes (71-73), stilbenes (81-84), pyranones (91-94), and
321	phenylbutanones (101 and 102). All of these constituents had a compound dose of \geq
322	$0.01 \ \mu mol/day$. Notably, these constituents were not detected in any other components
323	of LianhuaQingwen, except for gallic acid (42) which was also detected in the
324	component Hongjingtian (R. crenulata rhizomes and roots). The major constituents of
325	Dahuang were identified as chrysophanol (1), emodin-8- O - β -D-glucoside (2), rhein
326	(3), chrysophanol-8- O - β -D-glucoside (4), emodin (5), and
327	physcion-8- O - β -D-glucoside (6). These major constituents had a compound dose of
328	1.0-2.2 µmol/day. Moreover, LianhuaQingwen also exhibited lot-to-lot variations of
329	8.3%–12.1% for the major anthraquinones (1–6) and 6.6%–55.3% for the rest of the
330	minor constituents.

331

(Insert Figure 1 here)

332

2 3.2. Major circulating Dahuang compounds after dosing LianhuaQingwen and their

333 plasma pharmacokinetics: interspecies differences between humans and rats

334	Only two classes of compounds, i.e., anthraquinones and tannins, had significant
335	systemic exposure in humans following administration of LianhuaQingwen (Fig. 2
336	and Table 1), despite the presence of 55 Dahuang constituents of eight classes in the
337	capsule. Human systemic exposure to anthraquinones varied greatly, with unchanged
338	rhein (3) and methylisorhein (10) , rather than their metabolites, being the most
339	abundant in circulation. The other anthraquinones, including chrysophanol (1),
340	emodin-8- O - β -D-glucoside (2), chrysophanol-8- O - β -D-glucoside (4), emodin (5),
341	physcion-8-O-β-D-glucoside (6), chrysophanol-1-O-β-D-glucoside (7), physcion (8),
342	rhein-8- O - β -D-glucoside (9), and aloe-emodin (11), were either not detectable or
343	present in negligible levels in human plasma, either as unchanged compounds or
344	metabolites. The major circulating compound of tannins was 4-O-methylgallic acid
345	$(M42_{M2})$, which was a methylated metabolite of gallic acid (42), while 42 and its
346	other methylated metabolite 3-O-methylgallic acid $(M42_{M1})$ were detected at low
347	levels in plasma (Fig. 2). All circulating compounds were also detected in human
348	urine.

349

(Insert Figure 2 and Table 1 here)

The data presented in Fig. 2 highlights significant differences in the exposure profile of Dahuang anthraquinones between rats and humans when they received LianhuaQingwen. Although rhein (**3**) and methylisorhein (**10**) were the major circulating anthraquinones for both rats and humans, rats had additional circulating anthraquinones and their metabolites that either went undetected or were present in limited quantities in human plasma. These newly detected anthraquinones in rats

356	included chrysophanol (1), chrysophanol-1- O -glucuronide (M1 _{G1}),
357	chrysophanol-8- O -glucuronide (M1 _{G2}), rhein- O -glucuronide (M3 _{G1}),
358	emodin-3- O -glucuronide (M5 _{G3}), physcion-1- O -glucuronide (M8 _{G1}), and
359	physcion-8- O -glucuronide (M8 _{G2}). The major circulating compound in humans for
360	tannins was 4-O-methylgallic acid ($M42_{M2}$), while both $M42_{M2}$ and gallic acid (42)
361	were the major circulating compounds in rats. These findings suggest that the
362	systemic exposure to anthraquinones and tannins could differ considerably between
363	rats and humans, and that such differences should be taken into account when
364	evaluating the safety and efficacy of the Dahuang-containing herbal medicine in
365	preclinical studies.

Table 2 summarizes the plasma pharmacokinetics of major circulating Dahuang 366 367 compounds [rhein (3), methylisorhein (10), and 4-O-methylgallic acid $(M42_{M2})$] in humans who were given 12 capsules/day of LianhuaQingwen. As illustrated in Fig. 3, 368 both 3 and 10 showed unimodal plasma concentration-time profiles, reaching their 369 peak concentrations (T_{peak}) between 1 and 3 h. Females had a higher C_{max} and 370 371 AUC_{0-24h} for both **3** and **10** compared to males (P < 0.05), with all the data adjusted for body weight. There was no significant accumulation of 3 and 10 after 372 administering LianhuaQingwen for seven consecutive days (P > 0.05). As shown in 373 Table 2, renal clearance ratio $(R_{\rm rc})$ of 3 and 10 suggested that the renal excretion 374 375 involved tubular secretion, which was mediated by the renal basolateral SLC uptake 376 transporters OAT1, OAT2, and OAT3 (Tables 3 and S4). In addition, 10, but not 3, was also a substrate of the renal apical SLC uptake transporter OAT4, which could 377

378	induce tubular reabsorption of 10. The plasma concentration-time profiles of $M42_{M2}$
379	were similar to those of 3 and 10, as demonstrated in Table 2 and Fig. 3. The $R_{\rm rc}$ of
380	$M42_{M2}$ in Table 2 showed that its renal excretion involved tubular secretion, which
381	was also mediated by OAT1, OAT2, and OAT3 (Table 3).

382

(Insert Figure 3 and Tables 2 and 3 here)

383 *3.3 Factors governing the differential human systemic exposure to Dahuang*

384 anthraquinones: transporter-mediated intestinal absorption and LPH-mediated

385 *pre-absorption metabolism*

386 Membrane permeability was assessed using Caco-2 cell monolayer to understand 387 the factors governing differential human systemic exposure to the anthraquinones. 388 Rhein (3) and methylisorhein (10) showed moderate membrane permeability (Table 4). 389 Estimated water solubility of these two compounds (Table S5), in relation to their respective compound doses from LianhuaQingwen and Caco-2-based permeability, 390 391 was insufficient to achieve adequate intestinal absorption [35, 36]. Intestinal penetration of 3 and 10 could also be limited by human intestinal apical MDR1-, 392 BCRP-, and MRP2-mediated efflux into the intestinal lumen (Table 4 and Table S6). 393 394 However, human intestinal apical ASBT and TAUT could enhance intestinal absorption of these compounds into intestinal epithelia (Table 3), and human intestinal 395 396 basolateral MRP1, MRP3, and MRP4 could mediate the compounds' efflux into blood (Table S6). Rhein-8-O- β -D-glucoside (9), which had poor membrane permeability for 397 intestinal absorption, was not a substrate of ASBT or TAUT. However, this 398

anthraquinone glucoside was found to be a substrate of human intestinal LPH, which
could facilitate the pre-absorption deglycosylation of 9 into the absorbable 3. *In vitro*metabolism studies suggested that 3 and 10 were resistant to human hepatic
glucuronidation, sulfation, or oxidation (Fig. S1).

403

(Insert Figure 4 and Table 4 here)

404 In terms of the other anthraquinone constituents with a compound dose of > 0.3µmol/day, emodin-8-O-glucoside (2) and physcion (8) were found to have poor 405 membrane permeability, which limited their passive intestinal absorption. Although 406 407 chrysophanol (1), chrysophanol-8-O-glucoside (4), emodin (5), physcion-8-O-glucoside (6), chrysophanol-1-O-glucoside (7), and aloe-emodin (11) 408 409 showed high or intermediate permeability, 1, 5, 6, and 11 exhibited poor water 410 solubility, which could limit their passive intestinal absorption (Table S5). 411 Additionally, their pre-absorption deglycosylation by human intestinal LPH transforming 4 and 7 into unabsorbable 1 and the efflux action of intestinal apical 412 transporters on them restricted their passive intestinal penetration (Table 4). None of 413 these compounds was a substrate of ASBT or TAUT (Table 3). 414

415 *3.4.* Inhibitory activities, against SARS-CoV-2 3CL^{pro}, of circulating Dahuang

416 *compounds and other circulating compounds of LianhuaQingwen*

417 Rhein (**3**) and methylisorhein (**10**) inhibited $3CL^{pro}$ of SARS-CoV-2 with IC₅₀ 418 values of 4.6 and 37.2 µmol/L, respectively (Fig. 5). However, despite being tested at 419 100 µmol/L, other Dahuang compounds, such as 4-*O*-methylgallic acid (**M42**_{M2}),

420	gallic acid (42), and aloe-emodin (11), showed less than 50% inhibition of the viral
421	protease. Furthermore, following our prior and ongoing pharmacokinetic
422	investigations on LianhuaQingwen, we singled out several LianhuaQingwen
423	compounds originating from the capsule's other components and subjected them to
424	SARS-CoV-2 3CL ^{pro} inhibition tests. These compounds, unchanged or metabolized,
425	were glycyrrhetic acid, 24-hydroxyglycyrrhetic acid, ephedrine, pseudoephedrine,
426	hydroxytyrosol-3-O-sulfate, hydroxytyrosol, phillygenin, phillygenin-O-sulfate,
427	pinoresinol, and menthol-1-O-glucuronide and showed less than 50% inhibition of the
428	viral protease, despite being tested at 100 µmol/L.

429

(Insert Figure 5 here)

430 *3.5. Expression and cellular localization of Taut and Asbt in rat intestine and lung*

The specificity of the anti-TAUT and anti-ASBT antibodies was assessed using 431 432 Western Blot analysis. HEK-293 cells expressing human TAUT, human ASBT, rat Taut, or rat Asbt with a Flag-tag were used for the experiment. The Flag-tag antibody 433 434 successfully detected all four plasmids, confirming their expression in the cells. The anti-ASBT antibody recognized both human ASBT and rat Asbt, showing a band at 435 436 40 kDa. Similarly, the anti-TAUT antibody detected a band at 65 kDa for both human TAUT and rat Taut (Fig. 6A). These findings validate the reliability of the anti-ASBT 437 438 and anti-TAUT antibodies in detecting human ASBT/Asbt and TAUT/Taut proteins, 439 respectively. Furthermore, the protein expression levels of Asbt and Taut were examined in rat intestine, liver, and lung tissues using Western Blot analysis with 440

449	(Insert Figure 6)
448	membrane of epithelia in the intestinal villi (Fig. 6C).
447	membrane of bronchial epithelia. Both Asbt and Taut were found in the apical
446	whereas rat Taut was extensively found in the alveolar epithelia and basolateral
445	bronchial epithelia, rat Asbt was primarily localized on the basolateral membrane,
444	immunohistochemical analysis was performed on rat lung and intestine tissues. In the
443	the bronchus, while Taut exhibited high expression in the liver. Additionally,
442	lung, liver, and intestine tissues of rats (Fig. 6B). Rat Asbt showed high expression in
441	anti-ASBT and anti-TAUT antibodies. Both proteins were detected in the bronchus,

450 **4. Discussion**

For a complex Chinese herbal medicine, only a few key constituents with 451 452 drug-like properties are bioavailable at loci responsible for the medicine's therapeutic action, as opposed to all constituents [21]. Multi-compound pharmacokinetic 453 454 investigation is a useful approach to accurately identify such potential herbal 455 compounds without any omissions, relying on thorough comprehension of the medicine's chemical composition [37]. Such bioavailability of LianhuaQingwen 456 compounds was investigated to evaluate the medicine's efficacy and safety in treating 457 458 acute viral respiratory illnesses with respect to their systemic exposure and targeted reachability within the body [20]. As part of our multi-compound pharmacokinetic 459 460 researches on LianhuaOingwen, the previous investigation found that the major circulating Gancao compounds, glycyrrhetic acid and 24-hydroxyglycyrrhetic acid (a 461 metabolite), could reach and inhibit renal 462 Gancao distal new tubular 463 11β-hydroxysteroid dehydrogenase type 2, a target responsible for Gancao-induced 464 pseudoaldosteronism [20]. In the current investigation, a comprehensive analysis conducted and identified a total of 55 Dahuang constituents (≥0.01 µmol/day) in 465 466 LianhuaQingwen. However, among these constituents, only three exhibited significant systemic exposure in humans after dosing the capsule. These three 467 constituents were the anthraquinones rhein (3) and methylisorhein (10; a new 468 469 Dahuang anthraquinone), and the tannin 4-O-methylgallic acid (M42_{M2}). Interestingly, 470 the levels of the remaining anthraquinones and their metabolites, such as 471 chrysophanol (1), emodin (5), physcion (8), and aloe-emodin (11), were either 472 undetectable or found in very low quantities in human plasma. This significant variation in systemic exposure to Dahuang anthraquinones could be attributed to two 473

474 factors: transporter-mediated intestinal absorption and LPH-mediated main 475 pre-absorption metabolism. Dahuang anthraguinones, including 3 and 10, have poor water solubility, low membrane permeability, and/or intestinal apical efflux. These 476 477 properties hindered their passive absorption in the intestine, meaning they could not easily cross the intestinal membrane on their own. However, in the case of 3 and 10, 478 479 the human intestinal apical uptake transporters ASBT and TAUT, as well as the 480 human intestinal basolateral efflux transporters MRP1/3/4, could mediate their intestinal absorption and resulted in their significant systemic exposure in human after 481 482 dosing the capsule. It should be noted that other Dahuang anthraquinones did not exhibit human ASBT- or TAUT-mediated absorption. Additionally, the enzyme LPH 483 484 present in the human intestinal epithelia played a crucial role in facilitating the 485 transformation of rhein-8-O- β -D-glucoside (9) into readily absorbable 3. Interestingly, 486 this also transformed chrysophanol-8-*O*-β-D-glucoside enzyme (4) and chrysophanol-1-O- β -D-glucoside (7) into a non-absorbable 1, despite their favorable 487 488 characteristics of being highly water-soluble and easily permeable.

In addition to systemic exposure, targeted reachability of rhein (3) and 489 490 methylisorhein (10) was also an important factor for the efficacy of LianhuaQingwen capsule, a medication used in China to treat viral respiratory illnesses, including 491 492 severe acute respiratory syndrome (SARS), Middle East respiratory syndrome 493 (MERS), and coronavirus disease 2019 (COVID-19). Infections of SARS-CoV, MERS-CoV, and SARS-CoV-2 could cause severe respiratory pathologies and lung 494 495 injuries by infecting bronchial epithelial cells and pneumocytes in humans [38, 39]. 496 Therefore, it was crucial for the treatment to specifically target the lungs. The 3CL^{pro} 497 enzyme, due to its essential role in viral replication and high degree of conservation 498 across all coronaviruses, as well as its absence in human homologs, has been

499 identified as an attractive target for the development of drug against coronaviruses 500 such as SARS-CoV-2 [38, 40]. Rhein (3) and methylisorhein (10) demonstrated the ability to inhibit this enzyme, with IC₅₀ values of 4.6 and 37.2 µmol/L, respectively 501 (Fig. 5). Like their human counterparts, TAUT and ASBT, mentioned above in the 502 context of intestinal absorption of 3 and 10, rat Taut and rat Asbt was also found to 503 transport these two compounds (Fig. S2). The mRNA of human TAUT was found to 504 505 be widely expressed in various human tissues, such as the lungs, kidneys, and liver, 506 due to the recognized role of taurine, an endogenous substrate of TAUT, as an organic 507 osmolyte [41, 42]. In contrast, ASBT mRNA was exclusively detected in the human 508 ileum and kidney [43, 44]. Furthermore, the ASBT protein was found to be 509 predominantly located on the apical membrane of enterocytes in the human terminal 510 ileum [44, 45]. The intestinal TAUT and ASBT was considered a favorite target for 511 developing "drug inhibitor" to regulate the levels of bile acids, cholesterol, lipids, and glucose, or "drug substrate" to improve its oral bioavailability [46, 47]. Although the 512 513 precise localization of human TAUT and human ASBT proteins in lung epithelia 514 remains unclear, their rat orthologues, Asbt and Taut, was observed in alveolar 515 epithelia and the basolateral membrane of rat bronchial epithelia, as well as the apical membrane of epithelia in the intestinal villi in this investigation (Fig. 6). The uptake 516 517 of circulating 3 and 10 into lung epithelia could be expected to exert their potential 518 antiviral effects in humans. By targeting the lung epithelia and inhibiting the viral 519 protease enzyme in humans, these two compounds had the potential to combat 520 respiratory illnesses caused by coronaviruses such as SARS-CoV-2. Collectively, 521 systemic exposure to and targeted reachability of **3** and **10** could be significant factors in the efficacy of LianhuaQingwen capsule. Further research on pulmonary 522 523 localizations and genetic variations of TAUT and ASBT in humans will provide

additional insights into the mechanisms underlying the antiviral effects of **3** and **10**.

525 It is worth noting that systemic exposure to Dahuang anthraquinones and tannins may vary considerably between rats and humans after dosing LianhuaQingwen. While 526 rhein (3) and methylisorhein (10) were the primary anthraquinones found in both rat 527 and human plasma, rats exhibited additional circulating anthraquinones and their 528 metabolites, including rhein-O-glucuronide $(M3_{G1})$, that were either undetected or 529 530 present in limited quantities in human plasma. In humans, the principal circulating 531 compound for tannins was 4-O-methylgallic acid ($M42_{M2}$), while both $M42_{M2}$ and 532 gallic acid (42) were the major circulating compounds in rats. Glucuronidation was 533 the main metabolic pathway of anthraquinones, including 3, in rats after dosing a 534 Dahuang extract, while methylation was the main metabolic pathway of gallic acid 535 [48, 49]. Rhein was reported the only compound that humans were significantly 536 exposed to after orally dosing a Dahuang extract [50]. To date, the pharmacokinetic 537 mechanisms governing its significant systemic exposure, including its glucuronidation, 538 remain unclear in humans. Our investigation revealed that, apart from rhein being absorbed in the intestines through human ASBT/TAUT-mediated intestinal uptake 539 540 from the intestinal lumen and human MRP1/3/4-mediated intestinal efflux into the blood, poor metabolism of 3 in humans was found to be another factor contributing to 541 542 its significant systemic exposure. This was evident from our observation that there 543 was no significant difference in the systemic exposure to total 3 (including both free and conjugated forms) and free 3 in humans after oral administration of 544 545 LianhuaQingwen (Fig. S3). This finding was further supported by the observed poor 546 in vitro human hepatic glucuronidation, sulfation, and oxidation of 3 (Fig. S1). 547 Methylisorhein (10) exhibited a similar situation in humans. The intestinal absorption 548 of **3** and **10** in rats was also mediated by rat orthologues of human ASBT and human

549 TAUT. However, the molecular mechanisms by which other Dahuang anthraquinones 550 and their metabolites were significantly exposed in rats remain unclear. Due to practical and ethical concerns associated with human experimentation, the use of 551 552 animal models, specifically rats and mice, has become essential in antiviral research. These models are crucial for evaluating the safety and efficacy of antiviral drugs, in 553 554 addition to conducting in vitro studies on their antiviral activities. Safety concerns 555 arised due to the presence of the quinone moiety in the structure of these 556 anthraquinones. Studies have focused on the potential hepatotoxicity of Dahuang, specifically investigating its anthraquinones and tannins[6]. However, these 557 558 investigations have primarily relied on preclinical models, especially rat models [6, 559 51]. Even when assessing the toxicity of specific compounds like 3, the doses needed 560 to induce toxicity were considerably higher than the typical doses used in clinical 561 settings [51]. Therefore, such interspecies differences in systemic exposure to Dahuang anthraquinones should be taken into account when evaluating the safety and 562 563 efficacy of the Dahuang-containing herbal medicine in preclinical studies. Further research is needed to fully understand the implications of the interspecies differences 564 565 associated with molecular mechanisms, in order to accurately assess its potential benefits and risks in humans. 566

In the field of herbal medicine, anthraquinones are found in a diverse range of plant species, particularly in the families *Polygonaceae* (such as the Chinese medicinal herb Dahuang), *Fabaceae* (Juemingzi and Fanxieye), and *Rubiaceae* (Qiecao). Anthraquinones can be present in these herbs both in their free form as aglycones (like rhein) and bound to sugar residues (like rhein-8-*O*-β-D-glucoside). The quantity of free and glycosylated anthraquinones in herbal medicines can be affected by factors like the specific origin, variety, and processing methods of the

- 5 -

574 component herb. These variations in the active constituents of the herb can affect 575 quality and efficacy of the herbal medicines. For example, in the case of Dahuang, which includes the rhizomes and roots of R. palmatum L., R. tanguticum Maxim. ex 576 577 Balf., and R. officinale Baill. from the Polygonaceae family, the ratio of free and glycosylated rhein content can vary greatly, ranging from 0.001 to 65 [52]. In herbal 578 579 medicines rich in β -glycosylated anthraquinones, lactase or lactase-phlorizin 580 hydrolase (LPH, EC 3.2.1.23/62) plays a significant role in the hydrolysis of β -glycosylated anthraquinones to free anthraquinones (Fig. 4). This was demonstrated 581 582 by the significant systemic exposure of free rhein (rather than rhein-8-O- β -D-glucoside), with a short T_{max} value of 0.5 h, in rats after oral 583 584 administration of rhein-8-O-β-D-glucoside (Fig. S4). LPH is a primary β-glycosidase 585 located in the intestinal microvillus membrane and is responsible for the extracellular 586 hydrolysis of most β -glycosylated xenobiotics, such as glycosylated flavonoids [53]. This hydrolase is predominantly expressed in the jejunum, with lower levels of 587 588 expression in the proximal and distal ends of the intestines [54]. When the activity of intestinal LPH becomes inhibited or decreased, β -glycosylated anthraquinones reach 589 590 the colon. It is presumed that the colonic concentration of free anthraquinones increased, resulting in a higher likelihood of inducing local drug effects. This can be 591 592 attributed to the presence of colonic microbiota and the absence of intestinal uptake 593 transporters, such as ABST [44, 45]. Therefore, by understanding the content and extraction of free and glycosylated anthraquinones in herbal medicines, as well as the 594 595 role of LPH in their hydrolysis, researchers can better comprehend the potential 596 therapeutic effects and mechanisms of action of these anthraquinone-containing 597 medicinal plants.

598

599 **5.** Conclusion

In this investigation, we examined systemic exposure and targeted reachability of 600 601 Dahuang compounds in humans through a multi-compound pharmacokinetic 602 investigation of a Dahuang-containing medicine LianhuaQingwen. During the 603 investigation, 55 constituents ($\geq 0.01 \mu mol/day$), originating from Dahuang (R. palmatum rhizomes and roots), were identified and characterized in LianhuaQingwen. 604 However, only three Dahuang compounds - rhein (3), methylisorhein (10), and 605 606 4-O-methylgallic acid ($M42_{M2}$) - exhibited significant systemic exposure in humans 607 after dosing the capsule. Two absorption mechanisms for 3 and 10 across the small intestine have been proposed: active intestinal uptake of 3 and 10 by human 608 609 ASBT/TAUT and human MRP1/3/4, and gut-luminal hydrolysis of rhein-8-O- β -D-glucoside (9) by LPH, followed by the absorption of released 3 by the 610 intestinal transporters. Another contributing factor to their significant systemic 611 612 exposure was the poor metabolism of 3 and 10 in humans. In contrast, the other 613 anthraquinones and their metabolites were either undetectable or present in low 614 concentrations in human plasma. This can be attributed to their poor water solubility, 615 low membrane permeability, and/or intestinal apical efflux, which hindered their absorption in the intestines. Additionally, targeted reachability of circulating 3 and 10 616 could be achieved as rat orthologues of human ASBT/TAUT was observed in alveolar 617 618 epithelia and basolateral membrane of bronchial epithelia, where coronaviruses could infect and replicate. These two compounds showed potential ability to inhibit the 619 3CL^{pro} enzyme responsible for viral replication in coronaviruses. This suggested that 620 621 the compounds had potential use in treating respiratory illnesses caused by coronaviruses. It is important to note that the circulating Dahuang anthraquinones and 622

tannins differed significantly between humans and rats after dosing LianhuaQingwen.
This highlights the significance of considering interspecies differences when
evaluating the safety and efficacy of the Dahuang-containing medicines. Overall, this
investigation, along with similar studies on other components, contributes to defining
the therapeutic benefits of Dahuang-containing medicines. It also underscores the
need to establish conditions for the safe use of these medicines by considering
interspecies differences.

630 **CRediT** author statement

631 Nan-Nan Tian: Investigation, Validation, Formal analysis, Visualization; 632 Ling-Ling Ren: Investigation, Validation, Formal analysis, Visualization; Ya-Xuan 633 Zhu: Investigation, Validation, Formal analysis; Jing-Ya Sun: Investigation, Formal 634 analysis, Visualization; Jun-Lan Lu: Investigation, Validation; Jia-Kai Zeng: 635 Investigation, Validation; Feng-Qing Wang: Investigation; Fei-Fei Du: Investigation; 636 Xi-He Yang: Investigation; Shu-Ning Ge: Investigation; Rui-Min Huang: Conceptualization, Methodology, Formal analysis; Wei-Wei Jia: Investigation, 637 638 Validation, Formal analysis, Visualization, Conceptualization, Methodology, Writing -639 Original draft preparation, Reviewing and Editing, Project administration, Funding 640 acquisition; Chuan Li: Conceptualization, Methodology, Formal analysis, Writing -Original draft preparation, Reviewing and Editing, Supervision, Funding acquisition. 641

642

Declaration of competing interest

643 The authors declare that there are no conflicts of interest.

Acknowledgements 644

645 This work was funded by grants from the National Natural Science Foundation of China (Grant Nos.: 82074176 and 81503345), Innovation Team and Talents 646 647 Cultivation Program of National Administration of Traditional Chinese Medicine (Grant No.: ZYYCXTD-C-202009), and the National Key R&D Program of China 648 649 (Grant No.: 2018YFC1704500).

Supplementary data 650 Appendix A.

651

medRxiv preprint doi: https://doi.org/10.1101/2023.08.28.23294750; this version posted August 30, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

652 References

- 653 [1]. H. Xiang, J.X. Zuo, F.Y. Guo, et al. What we already know about rhubarb: a comprehensive 654 review, Chinese Medicine 15 (2020).
- 655 [2]. China Pharmacopoeia Commission. Chinese Pharmacopeia. Beijing, China: China Medical 656 Science Press; 2020:24-25.
- 657 [3]. K. Huang, P. Zhang, Z. Zhang, et al. Traditional Chinese Medicine (TCM) in the treatment of 658 COVID-19 and other viral infections: Efficacies and mechanisms, Pharmacol Ther 225 (2021) 659 107843.
- 660 [4]. W. Luo, X. Su, S. Gong, et al. Anti-SARS coronavirus 3C-like protease effects of Rheum 661 palmatum L. extracts, Biosci Trends 3 (2009) 124-126.
- 662 [5]. S. Das, A. Singh, S.K. Samanta, et al. Naturally occurring anthraquinones as potential inhibitors of 663 SARS-CoV-2 main protease: an integrated computational study, Biologia (Bratisl) 77 (2022) 664 1121-1134.
- 665 [6]. T. Zhuang, X. Gu, N. Zhou, et al. Hepatoprotection and hepatotoxicity of Chinese herb Rhubarb 666 667 (Dahuang): How to properly control the "General (Jiang Jun)" in Chinese medical herb, Biomed Pharmacother 127 (2020) 110224.
- 668 [7]. E.M. Clementi, F. Misiti. Potential health benefits of rhubarb. Bioactive foods in promoting health: 669 Elsevier; 2010:407-423.
- 670 [8]. F. Zhang, R. Wu, Y.F. Liu, et al. Nephroprotective and nephrotoxic effects of Rhubarb and their 671 molecular mechanisms, Biomedicine & Pharmacotherapy 160 (2023).
- 672 [9]. J.B. Wang, W.J. Kong, H.J. Wang, et al. Toxic effects caused by rhubarb (Rheum palmatum L.) are 673 reversed on immature and aged rats, J Ethnopharmacol 134 (2011) 216-220.
- 674 [10]. Chinese National Health Commission and Chinese State Administration of Traditional Chinese 675 Medicine. Diagnosis and treatment plan for influenza (2019 2019. version). 676 (http://www.nhc.gov.cn/yzygj/s7653p/201911/a577415af4e5449cb30ecc6511e369c7/files/75a810 713dc14dcd9e6db8b654bdef79.pdf) 677
- 678 [11]. National Health and Family Planning Commission of People's Republic of China. Gulideline on 679 diagnosis and treatment of Middle East respirotory syndrome (2015 version). Chin J Viral Dis 5 680 (2015) 352-354.
- 681 [12].K. Hu, W.J. Guan, Y. Bi, et al. Efficacy and safety of Lianhuaqingwen capsules, a repurposed 682 Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized 683 controlled trial, Phytomedicine 85 (2021) 153242.
- 684 [13].L. Zhang, L. Wu, X. Xu, et al. Effectiveness of Lianhua Qingwen Capsule in Treatment of 685 Asymptomatic COVID-19 Patients: A Randomized, Controlled Multicenter Trial, J Integr 686 Complement Med 28 (2022) 887-894.
- 687 [14].P. Shen, J. Li, S. Tu, et al. Positive effects of Lianhuaqingwen granules in COVID-19 patients: A 688 retrospective study of 248 cases, J Ethnopharmacol 278 (2021) 114220.
- 689 [15].S.J. Fan, J.K. Liao, L. Wei, et al. Treatment efficacy of Lianhua Qingwen capsules for eraly-stage 690 COVID-19, Am J Transl Res 14 (2022) 1332-1338.
- 691 [16].J. Wu, Q. Wang, L. Yang, et al. Potency of Lianhua Qingwen granule combined with paramivir 692 sodium chloride injection in treating influenza and level changes of serum inflammatory factors, 693 Am J Transl Res 13 (2021) 6790-6795.
- 694 [17].L. Runfeng, H. Yunlong, H. Jicheng, et al. Lianhuaqingwen exerts anti-viral and 695 anti-inflammatory activity against novel coronavirus (SARS-CoV-2), Pharmacol Res 156 (2020) 696 104761.

perpetuity. All rights reserved. No reuse allowed without permission.

- [18].X. Chen, Y. Wu, C. Chen, et al. Identifying potential anti-COVID-19 pharmacological components
 of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2
 biochromatography screening, Acta Pharm Sin B 11 (2021) 222-236.
- [19].C. Li, W.W. Jia, J.L. Yang, et al. Multi-compound and drug-combination pharmacokinetic research
 on Chinese herbal medicines, Acta Pharmacol Sin 43 (2022) 3080-3095.
- [20].X.F. Lan, O.E. Olaleye, J.L. Lu, et al. Pharmacokinetics-based identification of pseudoaldosterogenic compounds originating from *Glycyrrhiza uralensis* roots (Gancao) after dosing LianhuaQingwen capsule, Acta Pharmacol Sin 42 (2021) 2155-2172.
- [21].T. Lu, J. Yang, X. Gao, et al. Plasma and urinary tanshinol from Salvia miltiorrhiza (Danshen) can
 be used as pharmacokinetic markers for cardiotonic pills, a cardiovascular herbal medicine, Drug
 Metab Dispos 36 (2008) 1578-1586.
- [22].H. Liu, J. Yang, F. Du, et al. Absorption and disposition of ginsenosides after oral administration
 of Panax notoginseng extract to rats, Drug Metab Dispos 37 (2009) 2290-2298.
- [23].F. Chen, L. Li, F. Xu, et al. Systemic and cerebral exposure to and pharmacokinetics of flavonols and terpene lactones after dosing standardized Ginkgo biloba leaf extracts to rats via different routes of administration, Br J Pharmacol 170 (2013) 440-457.
- [24].Z. Hu, J. Yang, C. Cheng, et al. Combinatorial metabolism notably affects human systemic
 exposure to ginsenosides from orally administered extract of Panax notoginseng roots (Sanqi),
 Drug Metab Dispos 41 (2013) 1457-1469.
- [25].M. Li, F. Wang, Y. Huang, et al. Systemic exposure to and disposition of catechols derived from
 Salvia miltiorrhiza roots (Danshen) after intravenous dosing DanHong injection in human subjects,
 rats, and dogs, Drug Metab Dispos 43 (2015) 679-690.
- [26].C. Cheng, F. Du, K. Yu, et al. Pharmacokinetics and Disposition of Circulating Iridoids and
 Organic Acids in Rats Intravenously Receiving ReDuNing Injection, Drug Metab Dispos 44 (2016)
 1853-1858.
- [27].C. Cheng, J.Z. Lin, L. Li, et al. Pharmacokinetics and disposition of monoterpene glycosides
 derived from Paeonia lactiflora roots (Chishao) after intravenous dosing of antiseptic XueBiJing
 injection in human subjects and rats, Acta Pharmacol Sin 37 (2016) 530-544.
- [28].X. Li, C. Cheng, F. Wang, et al. Pharmacokinetics of catechols in human subjects intravenously
 receiving XueBiJing injection, an emerging antiseptic herbal medicine, Drug Metab
 Pharmacokinet 31 (2016) 95-98.
- [29].X.W. Liu, J.L. Yang, W. Niu, et al. Human pharmacokinetics of ginkgo terpene lactones and impact of carboxylation in blood on their platelet-activating factor antagonistic activity, Acta Pharmacol Sin 39 (2018) 1935-1946.
- [30].N. Zhang, C. Cheng, O.E. Olaleye, et al. Pharmacokinetics-Based Identification of Potential Therapeutic Phthalides from XueBiJing, a Chinese Herbal Injection Used in Sepsis Management, Drug Metab Dispos 46 (2018) 823-834.
- [31].J.Y. Dai, J.L. Yang, C. Li. Transport and metabolism of flavonoids from Chinese herbal remedy
 Xiaochaihu- tang across human intestinal Caco-2 cell monolayers, Acta Pharmacol Sin 29 (2008)
 1086-1093.
- [32]. W. Jia, F. Du, X. Liu, et al. Renal tubular secretion of tanshinol: molecular mechanisms, impact on its systemic exposure, and propensity for dose-related nephrotoxicity and for renal herb-drug interactions, Drug Metab Dispos 43 (2015) 669-678.
- [33].R. Jiang, J. Dong, X. Li, et al. Molecular mechanisms governing different pharmacokinetics of
 ginsenosides and potential for ginsenoside-perpetrated herb-drug interactions on OATP1B3, Br J
 Pharmacol 172 (2015) 1059-1073.
- [34].B. Davies, T. Morris. Physiological parameters in laboratory animals and humans, Pharm Res 10 (1993) 1093-1095.

perpetuity. All rights reserved. No reuse allowed without permission.

- [35].C.A. Lipinski. Drug-like properties and the causes of poor solubility and poor permeability, J
 Pharmacol Toxicol Methods 44 (2000) 235-249.
- [36]. W. Curatolo. Physical chemical properties of oral drug candidates in the discovery and exploratory
 development settings, Pharmaceutical Science & Technology Today 1 (1998) 387-393.
- [37].C. Li, C. Cheng, W. Jia, et al. Multi-compound pharmacokinetic research on Chinese herbal
 medicines: identifying potentially therapeutic compounds and characterizing their disposition and
 pharmacokinetics, Acta Pharmaceutica Sinica 56 (2021) 2426-2446.
- [38].P. V'Kovski, A. Kratzel, S. Steiner, et al. Coronavirus biology and replication: implications for
 SARS-CoV-2, Nat Rev Microbiol 19 (2021) 155-170.
- [39].M.Z. Tay, C.M. Poh, L. Renia, et al. The trinity of COVID-19: immunity, inflammation and intervention, Nat Rev Immunol 20 (2020) 363-374.
- [40].K. Anand, J. Ziebuhr, P. Wadhwani, et al. Coronavirus main proteinase (3CLpro) structure: basis
 for design of anti-SARS drugs, Science 300 (2003) 1763-1767.
- [41].S. Ramamoorthy, F.H. Leibach, V.B. Mahesh, et al. Functional characterization and chromosomal localization of a cloned taurine transporter from human placenta, Biochem J 300 (Pt 3) (1994) 893-900.
- [42].P. Singh, K. Gollapalli, S. Mangiola, et al. Taurine deficiency as a driver of aging, Science 380 (2023) eabn9257.
- [43].A.L. Craddock, M.W. Love, R.W. Daniel, et al. Expression and transport properties of the human
 ileal and renal sodium-dependent bile acid transporter, Am J Physiol 274 (1998) G157-169.
- [44].M. Drozdzik, C. Groer, J. Penski, et al. Protein abundance of clinically relevant multidrug
 transporters along the entire length of the human intestine, Mol Pharm 11 (2014) 3547-3555.
- [45].P. Hruz, C. Zimmermann, H. Gutmann, et al. Adaptive regulation of the ileal apical sodium dependent bile acid transporter (ASBT) in patients with obstructive cholestasis, Gut 55 (2006) 395-402.
- [46].M. Li, Q. Wang, Y. Li, et al. Apical sodium-dependent bile acid transporter, drug target for bile
 acid related diseases and delivery target for prodrugs: Current and future challenges, Pharmacol
 Ther 212 (2020) 107539.
- [47].D. Stary, M. Bajda. Taurine and Creatine Transporters as Potential Drug Targets in Cancer Therapy,
 International Journal of Molecular Sciences 24 (2023) 3788.
- [48].R. Song, L. Xu, F. Xu, et al. In vivo metabolism study of rhubarb decoction in rat using
 high-performance liquid chromatography with UV photodiode-array and mass-spectrometric
 detection: a strategy for systematic analysis of metabolites from traditional Chinese medicines in
 biological samples, J Chromatogr A 1217 (2010) 7144-7152.
- [49].C.S. Shia, S.H. Juang, S.Y. Tsai, et al. Metabolism and pharmacokinetics of anthraquinones in Rheum palmatum in rats and ex vivo antioxidant activity, Planta Med 75 (2009) 1386-1392.
- [50].J.H. Lee, J.M. Kim, C. Kim. Pharmacokinetic analysis of rhein in Rheum undulatum L, J
 Ethnopharmacol 84 (2003) 5-9.
- [51]. Y. Xu, X. Mao, B. Qin, et al. In vitro and in vivo metabolic activation of rhein and characterization
 of glutathione conjugates derived from rhein, Chem Biol Interact 283 (2018) 1-9.
- [52].K. Komatsu, Y. Nagayama, K. Tanaka, et al. Comparative study of chemical constituents of rhubarb from different origins, Chem Pharm Bull (Tokyo) 54 (2006) 1491-1499.
- [53].H. Elferink, J.P.J. Bruekers, G.H. Veeneman, et al. A comprehensive overview of substrate specificity of glycoside hydrolases and transporters in the small intestine : "A gut feeling", Cell Mol Life Sci 77 (2020) 4799-4826.
- [54].J.T. Troelsen. Adult-type hypolactasia and regulation of lactase expression, Biochim Biophys Acta
 1723 (2005) 19-32.

792 **Table 1**

793 Dahuang compounds, unchanged and metabolized, detected in human samples after orally dosing LianhuaQingwen.

Common d (ID)			LC/TOF-MS ^E data		Malassian fammula	Presence in human
Compound (ID)	$t_{\rm R}$ (min)	$[M-H]^{-}(m/z)$	Mass error (ppm)	Fragmentation profile (m/z)	Molecular formula	samples
Chrysophanol (1)	27.14	253.0511	4.0	225.0569, 183.0091	$C_{15}H_{10}O_4$	Plasma, urine
Chrysophanol-1-O-glucuronide (M1 _{G1})	19.24	429.0815	-1.6	253.0507, 225.0492, 183.0077	$C_{21}H_{18}O_{10}$	Plasma, urine
Chrysophanol-8-O-glucuronide (M1G2)	19.41	429.0822	0	253.0505, 225.0708, 183.0178	$C_{21}H_{18}O_{10}$	Plasma, urine
Emodin- O - β -D-glucoside (2)	18.94	431.0966	-2.8	269.0443, 225.1192	$C_{21}H_{20}O_{10}$	Plasma
Rhein (3)	23.61	283.0247	1.4	239.0348, 211.0422, 183.0411	$C_{15}H_{18}O_{6}$	Plasma, urine
Rhein-O-glucuronide-1 (M3 _{G1})	15.23	459.0563	-0.2	283.0244, 239.0339	$C_{21}H_{16}O_{12}$	Plasma, urine
Rhein-O-glucuronide-2 (M3G2)	16.93	459.0555	-2.0	283.0234, 239.0352	$C_{21}H_{16}O_{12}$	Urine
Emodin (5)	26.01	269.0455	1.9	241.0667, 225.0515, 197.0307	$C_{15}H_{10}O_5$	Plasma, urine
Emodin-O-glucuronide (M5G2)	19.53	445.0764	-1.6	269.0394, 225.0772	$C_{21}H_{18}O_{11}$	Plasma, urine
Emodin-3-O-glucuronide (M5 _{G3})	21.24	445.0776	1.1	269.0451, 225.0622	$C_{21}H_{18}O_{11}$	Plasma, urine
Physcion (8)	28.60	283.0605	-0.4	240.0323	$C_{16}H_{12}O_5$	Urine
Physcion-1-O-glucuronide (M8GI)	20.92	459.0924	-0.7	283.0599	$C_{22}H_{20}O_{11}$	Plasma
Physcion-8-O-glucuronide (M8 _{G2})	21.42	459.0923	-0.9	283.0607	$C_{22}H_{20}O_{11}$	Plasma, urine
Methylisorhein (10)	21.93	297.0392	-2.4	253.0485	$C_{16}H_{10}O_{6}$	Plasma, urine
Aloe-emodin (11)	21.81	269.0457	2.6	240.0364, 211.1301, 183.0977	$C_{15}H_{10}O_5$	Plasma, urine
Gallic acid (42)	3.73	169.0137	0	125.0227, 78.9810	$C_7H_6O_5$	Plasma, urine
3-O-Methylgallic acid (M42м1)	7.65	183.0297	2.2	168.0056, 139.0397, 124.0153	$C_8H_8O_5$	Plasma, urine
4-O-Methylgallic acid (M42 _{M2})	8.05	183.0299	3.3	168.0064, 139.0371, 124.0163	$C_8H_8O_5$	Plasma, urine
2,5-Dimethyl-7-hydroxychrome (91)	16.38	189.0556	2.1	174.0307, 146.0338	$C_{11}H_{10}O_3$	Plasma, urine

The details of human and rat studies and bioanalytical assay are described in the Supplementary Materials and methods.

794 **T**a 795 Ph

Table 2Pharmacokinetics of rhein (3), methylisorhein (10), and 4-O-methylgallic acid (M42_{M2}) in volunteers orally receiving LianhuaQingwen.

Pharmacokinetics	On day 1		On day 8	On day 8		
	Male (m1–m8)	Female (f9–f14)	Male (m1–m8)	Female (f9–f14)		
<i>Rhein (2)</i>						
$C_{\rm max}$ (nmol/L)	239.9 ± 68.6	286.7 ± 65.7	149.5 ± 30.6	277.0 ± 153.7		
$T_{\text{peak}}(\mathbf{h})$	2.5 ± 0.9	3.0 ± 0	3.1 ± 1.4	2.7 ± 0.8		
AUC _{0-24h} (h·nmol/L)	1469.3 ± 362.0	2103.9 ± 629.6	1013.3 ± 328.8	1933.6 ± 910.7		
$AUC_{0-\infty}$ (h·nmol/L)	1494.1 ± 368.9	2168.8 ± 659.2	1050.4 ± 370.3	2006.5 ± 934.9		
MRT (h)	6.9 ± 1.2	7.5 ± 1.7	7.4 ± 1.6	7.6 ± 1.6		
$t_{1/2}$ (h)	3.8 ± 0.7	4.8 ± 2.1	4.6 ± 0.8	4.2 ± 0.6		
$Cum.A_{e-U,0-48h}$ (nmol/kg)	7.9 ± 2.5	9.4 ± 3.9	8.5 ± 3.4	7.1 ± 1.9		
$CL_R (mL/h/kg)$	5.6 ± 1.6	4.6 ± 1.8	9.0 ± 4.7	4.5 ± 2.6		
R _{rc}	5.3 ± 1.5	4.3 ± 1.7	8.4 ± 4.3	4.2 ± 2.4		
Methylisorhein (10)						
$C_{\rm max}$ (nmol/L)	84.0 ± 16.5	126.6 ± 25.6	50.3 ± 11.0	115.2 ± 66.4		
$T_{\text{peak}}(\mathbf{h})$	4.5 ± 1.6	4.0 ± 1.5	4.9 ± 2.2	5.5 ± 2.3		
AUC _{0-24h} (h·nmol/L)	899.9 ± 180.2	1342.4 ± 339.3	624.3 ± 181.7	1210.6 ± 497.6		
$AUC_{0-\infty}$ (h·nmol/L)	1128.8 ± 264.6	1659.0 ± 486.6	767.2 ± 232.1	1418.2 ± 596.3		
MRT (h)	15.4 ± 3.0	17.8 ± 3.9	16.8 ± 2.4	13.8 ± 2.1		
$t_{1/2}$ (h)	9.5 ± 1.7	9.3 ± 1.3	9.1 ± 1.3	7.9 ± 0.7		
$Cum.A_{e-U,0-48h}$ (nmol/kg)	2.0 ± 0.8	3.6 ± 1.2	3.1 ± 1.4	3.6 ± 1.2		
$CL_R (mL/h/kg)$	2.2 ± 0.8	2.8 ± 1.1	5.5 ± 3.1	3.4 ± 1.8		
$R_{\rm rc}$	2.1 ± 0.8	2.6 ± 1.0	5.1 ± 2.9	3.2 ± 1.7		
4-O-Methylgallic acid ($M42_{M2}$)						
$C_{\rm max}$ (nmol/L)	119.0 ± 32.6	139.3 ± 32.7	96.7 ± 13.2	80.4 ± 21.2		
$T_{\text{peak}}(\mathbf{h})$	3.0 ± 0	2.7 ± 0.8	3.0 ± 0	3.0 ± 0		
AUC _{0-24h} (h·nmol/L)	463.0 ± 90.7	538.1 ± 99.4	341.6 ± 54.3	318.6 ± 86.3		
$AUC_{0-\infty}$ (h·nmol/L)	466.7 ± 91.0	540.1 ± 100.4	349.7 ± 55.9	320.7 ± 86.6		
MRT (h)	4.3 ± 0.4	3.8 ± 0.5	4.4 ± 0.5	4.0 ± 0.4		
$t_{1/2}$ (h)	1.4 ± 0.2	1.2 ± 0.4	1.9 ± 0.3	1.3 ± 0.3		
<i>Cum</i> . <i>A</i> _{e-U,0-48h} (nmol/kg)	55.9 ± 19.9	86.7 ± 25.8	53.9 ± 14.2	46.9 ± 25.2		
CL_{R} (mL/h/kg)	124.6 ± 49.3	159.6 ± 34.2	162.2 ± 49.8	142.6 ± 63.6		

	$R_{\rm rc}$	2.8 ± 1.1	3.6 ± 0.8	3.6 ± 1.1	3.2 ± 1.4	
--	--------------	---------------	---------------	---------------	---------------	--

 C_{max} , maximum plasma concentration; T_{peak} , the time taken to achieve the peak plasma concentration; AUC, area under the plasma concentration-time curve after dosing; MRT, mean residence time; $t_{1/2}$, terminal half-life; *Cum*. A_{e-U} , cumulative amount excreted into urine; CL_R, renal excretory clearance.

Table 3

Passive diffusion of Dahuang compounds in mock HEK-293 cells and their net transport ratios in HEK-293 cells transfected with various human intestinal or renal

800 transporters.

Compound (ID)	Transport in mock cell	Net transport ratio									
	(µL/min/mg protein)	TAUT	ASBT	OATP2B1	PEPT1	OAT1	OAT2	OAT3	OAT4	OCT2	PEPT2
Positive substrate		7.2 ± 1.5	200 ± 38	12.3 ± 2.4	17.6 ± 2.1	476 ± 57	24.1 ± 3.6	4.5 ± 0.3	7.6 ± 1.3	14.5 ± 2.6	54.9 ± 3.9
Chrysophanol (1)	8.8 ± 1.1	1.0 ± 0.1	0.9 ± 0.5	0.9 ± 0.3	2.2 ± 0.2	_	_	_	_		
Emodin-8- O - β -D-glucoside (2)	0.1 ± 0.0	2.1 ± 0.3	0.8 ± 0.1	3.6 ± 0.1	0.9 ± 0.1			_			_
Rhein (3)	0.2 ± 0.0	18.4 ± 2.7	5.9 ± 0.7	1.0 ± 0	0.7 ± 0.1	9.9 ± 1.0	8.4 ± 0.3	1.1 ± 0.1	1.8 ± 0.3	1.0 ± 0.2	1.7 ± 0.3
Chrysophanol-8- O - β -D-glucoside (4)	1.5 ± 0.2	0.8 ± 0.1	1.4 ± 0.1	2.0 ± 0.4	0.8 ± 0.1	_	_	_	_		
Emodin (5)	27.8 ± 1.6	1.0 ± 0.1	1.7 ± 0.4	1.6 ± 0.1	0.8 ± 0.2		_	_	_		
Physcion-8- O - β -D-glucoside (6)	6.0 ± 1.2	0.7 ± 0.1	1.0 ± 0.3	1.2 ± 0.2	0.8 ± 0.1		_	_	_		
Chrysophanol-1- O - β -D-glucoside (7)	1.4 ± 0.1	1.3 ± 0.4	1.2 ± 0.1	0.7 ± 0	1.5 ± 0.6		_	_	_		
Physcion (8)	9.4 ± 2.4	0.8 ± 0.1	1.8 ± 0.4	1.1 ± 0.1	1.2 ± 0.2		_	_	_		
Rhein-8- O - β -D-glucoside (9)	0.02 ± 0	0.8 ± 0.1	0.7 ± 0.4	0.7 ± 0	0.9 ± 0.1			_			_
Methylisorhein (10)	0.1 ± 0.0	7.7 ± 0.4	3.1 ± 0.3	2.4 ± 0.1	2.2 ± 0.1	8.1 ± 0.6	11.8 ± 0.3	5.7 ± 0.0	4.9 ± 1.1	1.3 ± 0.1	1.2 ± 0.3
Aloe-emodin (11)	24.8 ± 3.1	1.1 ± 0.3	1.2 ± 0.2	1.0 ± 0.1	1.4 ± 0.2		_	_	_		
Gallic acid (42)	0.01 ± 0	1.1 ± 0.2	1.2 ± 0.4	1.6 ± 0.5	0.5 ± 0	_		_			_
4-O-methylgallic acid (M42 _{M2})	0.03 ± 0				0.9 ± 0.3	73.2 ± 3.3	20.1 ± 0.8	5.5 ± 0.6	1.5 ± 0.1	0.6 ± 0.2	1.1 ± 0.2

801 For assessment of cellular uptake mediated by intestinal or renal transporters, differential transport rates between transfected cells and mock cells were defined as a net

802 transport ratio, which represents the mean \pm standard deviation (n = 3). A net transport ratio > 3 suggested a positive result. Positive substrates were taurocholic acid (ASBT),

803 [H³]-taurine (TAUT), estrone-3-sulfate (OATP2B1/OAT3/OAT4), glycylsarcosine (PEPT1/PEPT2), para-aminohippuric acid (OAT1), prostaglandin F_{2a} (OAT2),

804 tetraethylammonium (OCT2) and their final concentrations were 20 μmol/L with incubation time of 10 min.

805 Table 4 806

Apparent permeability for the investigational Dahuang compounds in Caco-2 cell monolayers.

	Without inhibitors		With inhibitors				
Compound	$P_{\rm app}$ (×10 ⁻⁶ cm/s)		EfR	$P_{\rm app}~(\times 10^{-6}~{\rm cm/s})$	EfR		
	Apical→Basolateral Basolateral→Apical			Apical→Basolateral	Basolateral→Apical		
Atenolol	0.8 ± 0.1	0.7 ± 0.1	0.9		_		
Antipyrine	33.1 ± 7.8	36.6 ± 6.4	1.1				
Rhodamine 123	0.8 ± 0.1	10.9 ± 1.2	14.0	0.3 ± 0.0	0.6 ± 0.0	1.9	
Sulfasalazine	0.6 ± 0.0	10.7 ± 1.7	17.5	0.8 ± 0.0	1.6 ± 0.1	1.9	
Estrone-3-sulfate	0.8 ± 0.2	7.4 ± 0.1	9.3	1.7 ± 0.1	1.4 ± 0.1	0.8	
Chrysophanol (1)	2.0 ± 0.5	3.9 ± 0.1	2.0				
Emodin-8- O - β -D-glucoside (2)	0.2 ± 0.0	2.7 ± 0.2	14.8	0.3 ± 0.1	0.9 ± 0.0	2.8	
Rhein (3)	5.5 ± 0.6	34.2 ± 1.8	6.3	7.8 ± 0.9	17.0 ± 4.7	2.2	
Chrysophanol-8- O - β -D-glucoside (4)	6.1 ± 0.2	25.6 ± 7.7	4.2	11.7 ± 0.9	10.2 ± 0.5	0.9	
Emodin (5)	18.6 ± 1.3	16.5 ± 4.0	0.9				
Physcion-8- O - β -D-glucoside (6)	0.6 ± 0.0	8.9 ± 1.3	14.9	1.2 ± 0.2	4.3 ± 0.9	3.5	
Chrysophanol-1- O - β -D-glucoside (7)	3.8 ± 0.5	22.0 ± 2.0	5.8	9.0 ± 0.2	7.2 ± 2.1	0.8	
Physcion (8)	0.4 ± 0.0	0.3 ± 0.0	0.9				
Rhein-8- O - β -D-glucoside (9)	0.3 ± 0.0	0.3 ± 0.1	1.1				
Methylisorhein (10)	1.4 ± 0.1	34.0 ± 3.7	24.0	4.0 ± 1.4	10.6 ± 2.3	2.6	
Aloe-emodin (11)	37.1 ± 3.6	32.4 ± 2.2	0.9				

Antipyrine, high permeability reference compound; atenolol, low permeability reference compound; rhodamine 123, P-gp probe substrate; sulfasalazine, MRP2 probe substrate; estrone-3-sulfate, BCRP probe substrate. Inhibitors, the mixture of verapamil (P-gp inhibitor), MK571 (MRP2 inhibitor), and novobiocin (BCRP inhibitor). An

807 808 809 efflux ratio (EfR) greater than 3 was considered as a positive result, suggesting that the investigational compound was an *in vitro* substrate of efflux transporter(s).

810 **Figure captions:**

811 Fig. 1. LianhuaQingwen constituents originating from Dahuang. (A) stacked liquid 812 chromatograms of anthraquinones (1-22), anthrones (31-34), tannins (41-52), flavonoids (61-64), naphthalenes (71-73), stilbenes (81-84), pyranones (91-94), and 813 phenylbutanones (101 and 102), detected by mass spectrometry, in a typical sample of 814 815 LianhuaQingwen; (B) constituents detected in a sample of raw material of Dahuang 816 (Rheum palmatum rhizomes and roots); (C) mean content levels of the constituents 817 detected in samples of 14 lots of LianhuaQingwen; (D) daily doses of the constituents from the lot A1802055 of LianhuaQingwen at the label daily dose 4.2 g/day; (E) 818 percentage daily doses of anthraquinones, anthrones, tannins, flavonoids, 819 820 naphthalenes, stilbenes, pyranones, and phenylbutanones in their respective total daily 821 dose of all the constituents of the class detected in LianhuaQingwen. 1, chrysophanol; 822 2, emodin-8-O-β-D-glucoside; 3, rhein; 4, chrysophanol-8-O-β-D-glucoside; 5, 823 emodin; 6, physcion-8-O-\beta-D-glucoside; and 10, methylisorhein. The names of the 824 other 48 constituents originating from Dahuang are shown in Table S3. The details of 825 composition analysis of LianhuaQingwen for constituents originating from Dahuang 826 are described in the Supplementary Materials and methods.

Fig. 2. Dahuang compounds detected in healthy volunteers and rats after orally dosing
LianhuaQingwen. (A and C) systemic exposure data; (B and D) renal excretion data;
(E) hepatobiliary excretion data. The dose for human volunteers was 12
capsules/person (A and B), while that for rats was 3.78 g/kg (C–E). Both unchanged
and metabolized Dahuang compounds were detected. 3, rhein; 10, methylisorhein,
M42_{M2}, 4-*O*-methylgallic acid. The names of the other Dahuang compounds detected
are shown in Table 1.

Fig. 3 Plasma concentration-time profiles of rhein (A and B), methylisorhein (C andD), and 4-O-methylgallic acid (E and F) in volunteers after dosing LianhuaQingwen

- 18 -


at 12 capsules/person. Solid dots, data of males; Open dots, data of females.
Pharmacokinetic data of these compounds are shown Table 2.

Fig. 4 In vitro human LPH-mediated deglycosylation of Dahuang anthraquinone 838 839 glycosides. LPH-mediated deglycosylation of the positive substrate phlorizin to 840 phloretin (A) and Dahuang compounds emodin-8-O-β-D-glucoside to emodin (B), chrysophanol-8-O-β-D-glucoside to chrysophanol (C), physcion-8-O-β-D-glucoside 841 842 to physcion (D), chrysophanol-1-O- β -D-glucoside to chrysophanol (E), and rhein-8-O-β-D-glucoside to rhein (F). Solid dots, glycosides; open dots, aglycones. 843 844 Other *in vitro* metabolism data of Dahuang compounds are shown in Supplementary 845 Fig. S1.

- Fig. 5 Inhibitory activities against of Dahuang compounds against SARS-CoV-2
 3CL^{pro}. (A) Percentage inhibition of 3CL^{pro} by circulating Dahuang compounds at 100
- 848 μ mol/L. (B) IC₅₀ of positive drug ebselen against 3CL^{pro}. (C and D) IC₅₀ of rhein and 849 methylisorhein against 3CL^{pro}, respectively.

850 Fig. 6 Expression and cellular localization of Taut and Asbt proteins in the rat 851 intestine and lung. (A) Western blot analysis of human ASBT, rat Asbt, human TAUT, or rat Taut proteins in the transfected HEK-293 cells. Representative autoradiographs 852 853 of the Western blots demonstrating 40-kDa human ASBT and rat Asbt protein bands 854 in the homogenates of human ASBT- and rat Asbt-transfected HEK293 cells, 855 respectively. Similarly, 65-kDa human TAUT and rat Taut proteins are observed in the 856 homogenates of human TAUT- and rat Taut-transfected HEK293 cells, respectively. 857 (B) Western blot analysis of Asbt and Taut proteins in rat lung, liver, and intestine 858 tissues. In the homogenates of these tissues, 40-kDa Asbt protein bands and 65-kDa 859 Taut protein bands are detected in rat bronchus, lung, liver, and intestine. (C) 860 Immunohistochemical localization of Asbt and Taut proteins in rat intestine and lung 861 tissues.

medRxiv preprint doi: https://doi.org/10.1101/2023.08.28.23294750; this version posted August 30, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



890 Fig. 1. LianhuaQingwen constituents originating from Dahuang. (A) stacked liquid chromatograms of 891 anthraquinones (1-22), anthrones (31-34), tannins (41-52), flavonoids (61-64), naphthalenes (71-73), 892 stilbenes (81-84), pyranones (91-94), and phenylbutanones (101 and 102), detected by mass 893 spectrometry, in a typical sample of LianhuaQingwen; (B) constituents detected in a sample of raw 894 material of Dahuang (Rheum palmatum rhizomes and roots); (C) mean content levels of the 895 constituents detected in samples of 14 lots of LianhuaQingwen; (D) daily doses of the constituents 896 from the lot A1802055 of LianhuaQingwen at the label daily dose 4.2 g/day; (E) percentage daily doses 897 of anthraquinones, anthrones, tannins, flavonoids, naphthalenes, stilbenes, pyranones, and 898 phenylbutanones in their respective total daily dose of all the constituents of the class detected in 899 LianhuaQingwen. 1, chrysophanol; 2, emodin-8-*O*-β-D-glucoside; 3. rhein; 4, 900 chrysophanol-8-O-B-D-glucoside; 5, emodin; 6, physcion-8-O-B-D-glucoside; and 10, methylisorhein. 901 The names of the other 48 constituents originating from Dahuang are shown in Table S3. The details of 902 composition analysis of LianhuaQingwen for constituents originating from Dahuang are described in 903 the Supplementary Materials and methods.

904

medRxiv preprint doi: https://doi.org/10.1101/2023.08.28.23294750; this version posted August 30, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.







Fig. 2. Dahuang compounds detected in healthy volunteers and rats after orally dosing
LianhuaQingwen. (A and C) systemic exposure data; (B and D) renal excretion data; (E) hepatobiliary
excretion data. The dose for human volunteers was 12 capsules/person (A and B), while that for rats
was 3.78 g/kg (C–E). Both unchanged and metabolized Dahuang compounds were detected. 3, rhein;
10, methylisorhein, M42_{M2}, 4-*O*-methylgallic acid. The names of the other Dahuang compounds
detected are shown in Table 1.





946 947 LianhuaQingwen at 12 capsules/person. (A and B), rhein; (C and D), methylisorhein; (E and F), 948 4-O-methylgallic acid. Solid dots, data of males; Open dots, data of females. Pharmacokinetic data of 949 these compounds are shown Table 2.






960 Fig. 4 In vitro human LPH-mediated deglycosylation of Dahuang anthraquinone glycosides. 961 Deglycosylation of the positive substrate phlorizin to phloretin (A) and Dahuang compounds 962 emodin-8-O-\beta-D-glucoside to emodin (B), chrysophanol-8-O-β-D-glucoside to chrysophanol (C), 963 physcion-8-O-β-D-glucoside to physcion (D), chrysophanol-1-O-β-D-glucoside to chrysophanol (E), 964 and rhein-8-O-β-D-glucoside to rhein (F). Solid dots, anthraquinone glycosides; open dots, the 965 respective free anthraquinones. Other in vitro metabolism data of Dahuang compounds are shown in 966 Supplementary Fig. S1.





982 Fig. 5 Inhibitory activities against of Dahuang compounds against SARS-CoV-2 3CLpro. (A) 983 Percentage inhibition of 3CL^{pro} by circulating Dahuang compounds at 100 µmol/L. (B) IC₅₀ of positive 984 drug ebselen against 3CL^{pro}. (C and D) IC₅₀ of rhein (3) and methylisorhein (10) against 3CL^{pro}, 985 respectively.



1013 Fig. 6 Expression and cellular localization of Taut and Asbt proteins in the rat intestine and lung. (A) 1014 Western blot analysis of human ASBT, rat Asbt, human TAUT, or rat Taut proteins in the transfected 1015 HEK-293 cells. Representative autoradiographs of the Western blots demonstrating 40-kDa human 1016 ASBT and rat Asbt protein bands in the homogenates of human ASBT- and rat Asbt-transfected 1017 HEK293 cells, respectively. Similarly, 65-kDa human TAUT and rat Taut proteins are observed in the 1018 homogenates of human TAUT- and rat Taut-transfected HEK293 cells, respectively. (B) Western blot 1019 analysis of Asbt and Taut proteins in rat lung, liver, and intestine tissues. In the homogenates of these 1020 tissues, 40-kDa Asbt protein bands and 65-kDa Taut protein bands are detected in rat bronchus, lung, 1021 liver, and intestine. (C) Immunohistochemical localization of Asbt and Taut proteins in rat intestine and 1022 lung tissues.